|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001 Email:nhsbsa.prescriptionservices@nhsbsa.nhs.ukWebsite:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  18 Nov 2024 |
|  |

VERSION 11.2.0

Dear dm+d User,

**Share your views - dm+d and SNOMED CT UK Drug Extension release cycles**

As part of the [UK Medicines Terminology Futures work](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures), we are seeking views from those who use or manage dm+d and/or SNOMED CT UK Drug Extension data, to understand preferences for release timings of the two terminologies and potential impacts if they were changed.

The purpose of obtaining views about release timings is to ensure we are meeting user needs, ensuring terminology information is cascaded at times to align with other dependencies and reduce burden, where possible.

**This is an opportunity to highlight your preferences and does not mean release timings will change.** If any release timings are to change, further impact analysis will take place to assess implementation options. **Any change would not take place until at least summer 2025.**

Supporting information about this work can be found on the [dm+d and SNOMED CT UK Drug Extension release cycles](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/survey-dm-d-and-snomed-ct-uk-drug-extension-release-cycles) webpage.

We have produced a [survey](https://forms.office.com/Pages/ResponsePage.aspx?id=slTDN7CF9UeyIge0jXdO4-zokzbQpLFJhG318l97n0xURUdCR1pMVkFPUzAwNk1HVlpFRU8yTEI1Ti4u) and would really value your insights and feedback by **5pm Friday 6 December 2024**.

If you have any issues completing the survey or would like to discuss this work further, please contact nhsdigital.ukmeds@nhs.net

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

We are providing an update to information posted in [September](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1113177&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension.

The VTM Ingredient XML file will be maintained from Monday 18 November and the VTM Ingredients that need populating will be gradually added over a period of time.  We will provide confirmation when this has been completed.

The weekly dm+d extract will be added to the NHS Terminology Server as usual and will include the live VTM Ingredients XML file.

**Please note that VTM Ingredients information will only be available via TRUD from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.**

Additional information about the change is available on the following [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact nhsdigital.ukmeds@nhs.net

**SNOMED International consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies**

We are providing an update to the information posted in [September](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1114489&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the inactivation of Medicinal Product therapeutic role groupers.

NHS England have reactivated the remaining [18 Medicinal Product Role Groupers](https://nhsengland.kahootz.com/gf2.ti/f/762498/222812261.1/XLSX/-/18%20Medicinal%20Product%20Role%20Groupers%20within%20the%20Allergy%20Archetypes%20Drug%20Groups%20simple%20reference%20s.xlsx) in release 39.1.0, release date 30 October 2024, to support the **Allergy Archetypes Drug Groups simple reference set.**

If you have any questions, please email information.standards@nhs.net adding ‘Inactivation of Therapeutic Role Groupers in the Medicinal Product Hierarchy’ to the subject line.

**SNOMED International Proposal to Increase Description Length Limit**

We are providing an update to the [information previously communicated](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1061497&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136%26startRow%3D11) regarding the proposal from SNOMED International to increase the maximum length of Fully Specified Name and Synonym descriptions, from 255 to 4096 characters.

SNOMED International have provided further information about the proposal and **extended the deadline for feedback to 31 December 2024.**

As the UK Member’s National Release Centre, NHS England is collating feedback from SNOMED CT users in the UK on behalf of SNOMED International.

To access the new information and to submit your feedback, go to the [Delen news article](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

The deadline for survey responses is **5pm Tuesday, 31 December 2024**.

This proposal will not impact the dm+d, we are not planning to make any changes to the dm+d as a result of this proposal from SNOMED International.

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact medicinestandards@nhs.net for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  |  14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order |  21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported |  27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported |  27/03/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) |  27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) |  27/11/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) |  11/12/2023 |
| Hydrogen peroxide 3% solution  | 42510811000001109 | Imported |  18/12/2023 |
| Cerium nitrate hexahydrate 22mg/g / Sulfadiazine silver 10mg/g cream | 42991011000001101 | Imported |  01/07/2024 |
| Sulfadiazine silver 1% cream  | 42990711000001107 | Imported | 01/07/2024 |
| Creon 10000 capsules | 43034611000001101 | Imported | 15/07/2024 |
| Creon 25000 capsules | 43034811000001102 | Imported | 15/07/2024 |
| Pancreaze Delayed-Release capsules | 43035111000001108 | Imported | 15/07/2024 |
| Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 43093511000001105 | Imported | 22/07/2024 |
| Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 43094411000001109 | Imported | 22/07/2024 |
| Gonadorelin 100microgram powder for solution for injection vials | 43145311000001103 | Imported | 29/07/2024 |
| Methylphenidate 18mg modified-release tablets | 43210911000001100 | Imported  | 02/09/2024 |
| Methylphenidate 27mg modified-release tablets | 43211511000001100 | Imported | 02/09/2024 |
| Methylphenidate 36mg modified-release tablets | 43211911000001107 | Imported | 02/09/2024 |
| Methylphenidate 54mg modified-release tablets | 43212411000001109 | Imported | 02/09/2024 |
| Disopyramide 250mg modified-release tablets | 42441311000001105 | Imported | 16/09/2024 |
| Disopyramide 100mg capsules | 43669311000001107 | Imported | 16/09/2024 |
| Pangrol 10,000 capsules | 43788211000001100 | Imported | 23/09/2024 |
| Pangrol 25,000 capsules | 43788511000001102 | Imported | 23/09/2024 |

**Invalidation****s**

The following concepts have been invalidated. The dm+d Authoring Team understands that these concepts are now not sugar free and so invalidations and re-authoring has now been completed as necessary.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (not to be invalidated) | **VMP**Co-amoxiclav 125mg/31mg/ml oral suspension |
| **VMP SNOMED ID**36565811000001104 | **VMP SNOMED ID**7322211000001104 |
| **VMPP**100ml (not to be invalidated) | **VMPP**100ml |
| **VMPP SNOMED ID**1019711000001109 | **VMPP SNOMED ID**7320011000001105 |
| **AMP & AMP SNOMED IDs**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (A A H Pharmaceuticals Ltd)**829311000001103**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Alliance Healthcare (Distribution) Ltd)**370711000001105**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Almus Pharmaceuticals Ltd)**9787711000001107**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Colorama Pharmaceuticals Ltd)**22602311000001108**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Medihealth (Northern) Ltd)**38850811000001105**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Phoenix Healthcare Distribution Ltd)**17885411000001101**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Sandoz Ltd)**6032711000001109**Augmentin 125/31 SF oral suspension (GlaxoSmithKline UK Ltd)**932211000001108** | **AMP & AMP SNOMED IDs**Co-amoxiclav 125mg/31mg/5ml oral suspension (A A H Pharmaceuticals Ltd)**13613111000001106**Co-amoxiclav 125mg/31mg/5ml oral suspension (Alliance Healthcare (Distribution) Ltd)**43645711000001100**Co-amoxiclav 125mg/31m/5ml oral suspension (Almus Pharmaceuticals Ltd)**43646111000001107**Co-amoxiclav 125mg/31mg/5ml oral suspension (Colorama Pharmaceuticals Ltd)**43646511000001103**Co-amoxiclav 125mg/31mg/5ml oral suspension (Medihealth (Northern) Ltd)**38848811000001105**Co-amoxiclav 125mg/31mg/5ml oral suspension (Phoenix Healthcare Distribution Ltd)**43647511000001101**Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free (Sandoz Ltd)**43647811000001103**Augmentin 125/31 oral suspension (GlaxoSmithKline UK Ltd)**43646911000001105** |
| **AMPP**100ml | **AMPP**100ml |
| **AMPP SNOMED ID**1476711000001102 (A A H Pharmaceuticals Ltd)1478111000001104 (Alliance Healthcare (Distribution) Ltd)9787811000001104 (Almus Pharmaceuticals Ltd)22602411000001101 (Colorama Pharmaceuticals Ltd)38851011000001108 (Medihealth (Northern) Ltd)17885511000001102 (Phoenix Healthcare Distribution Ltd)6067511000001107 (Sandoz Ltd)1478011000001100 (GlaxoSmithKline UK Ltd) | **AMPP SNOMED ID**13613211000001100 (A A H Pharmaceuticals Ltd)43645911000001103 (Alliance Healthcare (Distribution) Ltd)43646311000001109 (Almus Pharmaceuticals Ltd)43646711000001108 (Colorama Pharmaceuticals Ltd)38848911000001100 (Medihealth (Northern) Ltd)43647611000001102 (Phoenix Healthcare Distribution Ltd)43647911000001108 (Sandoz Ltd)43647111000001105 (GlaxoSmithKline UK Ltd) |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (not to be invalidated) | **VMP**Co-amoxiclav 250mg/62mg/5ml oral suspension |
| **VMP SNOMED ID**37083611000001104 | **VMP SNOMED ID**7322311000001107 |
| **VMPP**100ml (not to be invalidated) | **VMPP**100ml |
| **VMPP SNOMED ID**960711000001107 | **VMPP SNOMED ID**7320311000001108 |
| **AMP & AMP SNOMED IDs**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (A A H Pharmaceuticals Ltd)**732211000001103**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Alliance Healthcare (Distribution) Ltd)**394111000001107**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Almus Pharmaceuticals Ltd)**9787911000001109**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Phoenix Healthcare Distribution Ltd)**17885611000001103**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Sandoz Ltd)**6034811000001107**Augmentin 250/62 SF oral suspension (GlaxoSmithKline UK Ltd)**866111000001100**Augmentin 250/62 SF oral suspension (Sigma Pharmaceuticals Plc)**19692311000001101** | **AMP & AMP SNOMED IDs**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (A A H Pharmaceuticals Ltd)**11528611000001104**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Alliance Healthcare (Distribution) Ltd)**43645611000001109**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Almus Pharmaceuticals Ltd)**43646011000001106**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Phoenix Healthcare Distribution Ltd)**43646811000001100**Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free (Sandoz Ltd)**43647211000001104**Augmentin 250/62 SF oral suspension (GlaxoSmithKline UK Ltd)**43646411000001102**Augmentin 250/62 SF oral suspension (Sigma Pharmaceuticals Plc)**43647411000001100** |
| **AMPP**100ml | **AMPP**100ml |
| **AMPP SNOMED ID**1471011000001106 (A A H Pharmaceuticals Ltd)1474111000001105 (Alliance Healthcare (Distribution) Ltd)9788011000001106 (Almus Pharmaceuticals Ltd)17885711000001107 (Phoenix Healthcare Distribution Ltd)6035211000001107 (Sandoz Ltd)1473811000001101 (GlaxoSmithKline UK Ltd)19692411000001108 (Sigma Pharmaceuticals Plc) | **AMPP SNOMED ID**11528711000001108 (A A H Pharmaceuticals Ltd)43645811000001108 (Alliance Healthcare (Distribution) Ltd)43646211000001101(Almus Pharmaceuticals Ltd)43647011000001109 (Phoenix Healthcare Distribution Ltd)43647311000001107 (Sandoz Ltd)43646611000001104 (GlaxoSmithKline UK Ltd)43647711000001106 (Sigma Pharmaceuticals Plc) |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Co-amoxiclav 400mg/57mg/5ml oral suspension sugar free (not to be invalidated) | **VMP**Co-amoxiclav 400mg/57mg/5ml oral suspension |
| **VMP SNOMED ID**37083711000001108 | **VMP SNOMED ID** |
| **VMPP**35ml (not to be invalidated)70ml (not to be invalidated) | **VMPP**35ml70ml |
| **VMPP SNOMED ID**12984110000011001030511000001103 | **VMPP SNOMED ID**4364801100000110543648111000001106 |
| **AMP & AMP SNOMED IDs**Co-amoxiclav 400mg/57mg/5ml oral suspension (Medihealth (Northern) Ltd)**38850411000001108**Co-amoxiclav 400mg/57mg/5ml oral suspension (Sandoz Ltd)**22036711000001105**Co-amoxiclav 400mg/57mg/5ml oral suspension (Sigma Pharmaceuticals Plc)**15077811000001102**Augmentin-Duo 400/57 oral suspension (GlaxoSmithKline UK Ltd)**169511000001107**Augmentin-Duo 400/57 oral suspension (Sigma Pharmaceuticals Plc)**14199011000001106** | **AMP & AMP SNOMED IDs**Co-amoxiclav 400mg/57mg/5ml oral suspension (Medihealth (Northern) Ltd)**43648211000001100**Co-amoxiclav 400mg/57mg/5ml oral suspension (Sandoz Ltd)**43649011000001100**Co-amoxiclav 400mg/57mg/5ml oral suspension (Sigma Pharmaceuticals Plc)**43649511000001108**Augmentin-Duo 400/57 oral suspension (GlaxoSmithKline UK Ltd)**43648511000001102**Augmentin-Duo 400/57 oral suspension (Sigma Pharmaceuticals Plc)**43649311000001102** |
| **AMPP**35ml70ml | **AMPP**35ml70ml |
| **AMPP SNOMED ID**39847011000001103 (35ml) (Medihealth (Northern) Ltd)38850611000001106 (70ml) (Medihealth (Northern) Ltd)22036911000001107 (35ml) (Sandoz Ltd)22037011000001106 (70ml) (Sandoz Ltd)15078011000001109 (35ml) (Sigma Pharmaceuticals Plc)15078311000001107 (70ml) (Sigma Pharmaceuticals Plc)1468211000001100 (35ml) (GlaxoSmithKline UK Ltd)1468411000001101 (70ml) (GlaxoSmithKline UK Ltd)14199111000001107 (70ml) (Sigma Pharmaceuticals Plc) | **AMPP SNOMED ID**43648311000001108 (35ml) (Medihealth (Northern) Ltd)43648411000001101 (70ml) (Medihealth (Northern) Ltd)43649111000001104 (35ml) (Sandoz Ltd)43649211000001105 (70ml) (Sandoz Ltd)43649611000001107 (35ml) (Sigma Pharmaceuticals Plc)43649711000001103 (70ml) (Sigma Pharmaceuticals Plc)43648611000001103 (35ml) (GlaxoSmithKline UK Ltd)43648711000001107 (70ml) (GlaxoSmithKline UK Ltd)43649411000001109 (70ml) (Sigma Pharmaceuticals Plc) |

**Advance Notice of Invalidations**

None

dm+d Authoring Team